Characterization of Interferon Beta -1b-Induced Tolerizing Effect in Dendritic Cells

University of North Carolina, Chapel Hill56 enrolled

Overview

Determine the in-vivo mechanism of action of INF-B-1b as it's mechanisms of action are not completely understood. We propose that high dose exogenous recombinant IFN-B-1b induces tolerizing effect on DC-dependent T-cell differentiation in patients with MS by inducing the expression of SOCS3 in DCs.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Multiple Sclerosis

Interventions

IFNbeta-1bOTHER

no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Confirmed diagnosis of MS * Age 18-60 years, inclusive * Expanded disability status of 0-6.5 * Give written informed consent prior to any testing under this protocol

Locations (1)

University of North Carolina

Chapel Hill, North Carolina, United States

Outcomes

Primary Outcomes

Determine the effect of IFN-B-1b-induced SOCS3 upregulation in DCs' on their maturation and the capacity to present

Time frame: 2 years

Secondary Outcomes

Characterize the effect of IFN-1b-induced SOCS3 expression in DCs on Th1/Th2 cell differentiation and T-cell cytokine transcription.

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.